Skip to content

Phase I Study Evaluating The Safety And Efficacy of a Device for Collection of Electrical Bioimpedance Data

A Prospective, Single-Center, Phase I Study Evaluating the Safety and Initial Efficacy of the Epidetect Device for Collection of Bioimpedance Data of Human Tissues in Patients Undergoing Elective Pain Relief Treatment of Lumbar Epidural Steroid Injection Under Fluoroscopy

Status
UNKNOWN
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00746915
Enrollment
20
Registered
2008-09-04
Start date
2009-03-31
Completion date
2009-07-31
Last updated
2009-06-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain

Keywords

Patients undergoing elective pain relief treatment of lumbar epidural steroid injection under fluoroscopy

Brief summary

The objectives of this study are to evaluate the safety and initial efficacy of the epidural injection procedure when combined with real-time multi-frequency bio-impedance measurements that collect data on the electrical bioimpedance characteristics of living human tissue on the path of the epidural needle.

Interventions

DEVICEEpiDetect

During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.

Sponsors

ImpediGuide Ltd
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. Male or females 18 - 60 years of age 2. Imaging spine study (CT or MRI) in previous 3 months. 3. American Society of Anesthesiologists (ASA) class I-III 4. Patients undergoing elective standard pain relief treatment of Epidural Steroid Injection 5. Patients must be willing to participate in the study, and provide written informed consent 6. Women of child bearing potential must have a negative pregnancy test during the screening and baseline visits or the patient must be surgically sterile or be at least one year postmenopausal 7. Women of child-bearing potential must be using a medically acceptable method of birth control throughout the study such as: bilateral tubal ligation or the use of either a contraceptive implant, a contraceptive injection, an intrauterine device, or an oral contraceptive that has been taken for at least three months, which the subject agrees to continue using during the study, or a double-barrier method which must consist of a combination of any two of the following: diaphragm, cervical cap, condom or spermicide.

Exclusion criteria

1. Any contraindications for epidural injection 2. Patient with severe scoliosis 3. Previous spinal surgery, or any additional surgical intervention in the level of epidural injection other than elective standard pain relief treatment of Epidural Steroid Injection. 4. Documented, known or per examination neurological deficiency in lower extremities. 5. Pregnant or breastfeeding patients 6. Patients who have participated in another study within 30 days of enrolment 7. Investigator's opinion that the patient is medically unfit or would be at major risk if enrolled into the study i.e. known coagulopathy or recent use of anticoagulants or anti aggregates. 8. Presence of fever, sepsis or infection near the point of insertion or an infection in the bloodstream which may seed onto the catheter 9. Patients with known Hypovolemia 10. Any known Anatomical abnormalities, such as spina bifida, meningomyelocele or scoliosis 11. Patient suffering problems of the central nervous system, including multiple sclerosis or syringomyelia 12. Patients with identified heart-valve problems 13. Patients excessively hirsute where the surface electrodes are to be placed that are unwilling to shave these areas.

Design outcomes

Primary

MeasureTime frame
Safety variables collected will include the incidence of adverse events presented by severity, by seriousness and by relationship to study treatment2 weeks and 1 month post op

Secondary

MeasureTime frame
Obtaining real-time bioimpedance measurements in multiple frequencies within the range of 1kHz to 500kHz from human tissues crossed in the epidural needle path.Day of procedure

Countries

Israel

Contacts

Primary ContactElyad Davidson, Dr.
edavidson@hadassah.org.il(+972)-2-6776911

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026